These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 10691600)
21. Combination drug therapy for combined hyperlipidemia. Guyton JR Curr Cardiol Rep; 1999 Sep; 1(3):244-50. PubMed ID: 10980849 [TBL] [Abstract][Full Text] [Related]
22. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Karnik NS; Maldonado JR Psychosomatics; 2005; 46(6):565-8. PubMed ID: 16288136 [No Abstract] [Full Text] [Related]
23. Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review. Satarasinghe RL; Ramesh R; Riyaaz AA; Gunarathne PA; de Silva AP Drug Metabol Drug Interact; 2007; 22(4):279-83. PubMed ID: 18447003 [TBL] [Abstract][Full Text] [Related]
25. [Myositis, hypothyroidism and fibrates]. Wechsler B; Doumith R; Weil M Rev Med Interne; 1991; 12(6):475. PubMed ID: 1792441 [No Abstract] [Full Text] [Related]
26. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958 [TBL] [Abstract][Full Text] [Related]
27. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others? Stirling CM; Isles CG Nephrol Dial Transplant; 2001 Apr; 16(4):873-4. PubMed ID: 11274299 [No Abstract] [Full Text] [Related]
28. [Gemfibrozil induced rhabdomyolysis in a patient with undiscovered hypothyroidism]. Barquero-Romero J; Rodríguez Vázquez C; Arrobas Vacas I An Med Interna; 2006 Oct; 23(10):504-5. PubMed ID: 17205640 [No Abstract] [Full Text] [Related]
30. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177 [TBL] [Abstract][Full Text] [Related]
31. FDA adverse event reports on statin-associated rhabdomyolysis. Omar MA; Wilson JP Ann Pharmacother; 2002 Feb; 36(2):288-95. PubMed ID: 11847951 [TBL] [Abstract][Full Text] [Related]
32. A questionnaire assessment of physical function in hyperlipidemic patients. Taylor-Gjevre RM; Wassef A; Nair B; Gjevre JA; Wilson T Clin Invest Med; 2010 Aug; 33(4):E261-5. PubMed ID: 20691144 [TBL] [Abstract][Full Text] [Related]
33. [Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents]. Franc S; Bruckert E; Giral P; Turpin G Presse Med; 1997 Dec; 26(38):1855-8. PubMed ID: 9569908 [TBL] [Abstract][Full Text] [Related]
34. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Lee AJ; Maddix DS Ann Pharmacother; 2001 Jan; 35(1):26-31. PubMed ID: 11197581 [TBL] [Abstract][Full Text] [Related]
39. Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. Pedro-Botet J; Millán Núñez-Cortés J; Chillarón JJ; Flores-Le Roux JA; Rius J Expert Opin Drug Saf; 2016 Dec; 15(12):1583-1587. PubMed ID: 27645494 [TBL] [Abstract][Full Text] [Related]
40. Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia. Chen CL; Pan TM Food Chem; 2012 Sep; 134(2):1074-80. PubMed ID: 23107730 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]